Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ: XERS )

4.310 +0.030 (+0.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Socket Mobile And 3 Other Stocks Under $3 Insiders Are Buying
Via Benzinga
XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024
XERS stock results show that Xeris Biopharma Holdings missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
Via ACCESSWIRE
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Why Xeris Biopharma Shares Are Trading Higher Today
Xeris Biopharma Holdings Inc (NASDAQ: XERS) shares are trading higher by around 9% after the 
Via Benzinga
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Why Are Xeris Biopharma Shares Moving Monday?
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and... 
Via Benzinga
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
Via Benzinga
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down
Chewy stock is falling on Wednesday after it was announced that Morgan Stanley is handling a block sale of CHWY shares. 
Via InvestorPlace
Why Is Xeris Biopharma (XERS) Stock Up 12% Today?
Xeris Biopharma stock is rising higher on Wednesday as investors in XERS shares react to a new exclusive worldwide license agreement. 
Via InvestorPlace
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
From Xeris Biopharma Holdings, Inc.
Via Business Wire
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market. 
Via InvestorPlace
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 150 points on Thursday. Shares of Lamb Weston Holdings, Inc. (NYSE: LW) rose during Thursday’s session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
Xeris Biopharma Updates Its Outlook for 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports Third Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.